Biosimilars ‒ Policy failings that deny savings to countries that need it most
Competitor drugs entering the market are opening opportunities to make important savings on an increasing number of biological anticancer agents. But, as Rachel Brazil reports, many countries, including those with the most stretched health budgets, [more]
